Quintiles' Dennis Gillings to Become World Dementia Envoy
Dennis Gillings, PhD, Executive Chairman of Quintiles, has been appointed the first world dementia envoy.
Dennis Gillings, PhD, Executive Chairman of Quintiles, has been appointed the first world dementia envoy, according to reports on Friday in the UK media. Gillings plans to create a World Dementia Council to stimulate innovation and development of treatment for those with dementia.
The appointment, announced by Prime Minister David Cameron, follows an agreement between the G8 countries at a dementia summit in London in December, noted an article on the BBC news web site.
Gillings founded Quintiles in 1982, which grew out of his consulting activities with the pharmaceutical industry, and he took the company public on NASDAQ in 1994 and led its privatization in 2003. He served for more than 15 years as a professor at the University of North Carolina at Chapel Hill and received the Honorary Degree of Doctor of Science in May 2001. Also, he was the founding Chairman of the Association of Clinical Research Organizations, a Washington-based trade group formed in 2002.
Speaking for the opposition to the UK Government, Liz Kendall, the UK Labor Party’s shadow minister for care and older people, said she supported the Prime Minister's commitment to dementia research, but warned that more needed to be done to help those struggling with dementia now.
She told the BBC: "£2.7 billion ($4.51 billion) has been cut from council care budgets under this government, hitting the quality of life of hundreds of thousands of people with dementia and their families. The Prime Minister cannot credibly claim to show leadership on dementia unless he tackles poor care standards, like the increasing number of 15-minute home visits which are barely enough time to make a cup of tea, let alone help a frail, elderly person with dementia get up, washed, dressed and fed."
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
